Revvity earnings: guidance and what to watch
MyStockButler's October 2026 analysis: Revvity's next results are expected on November 3, 2026. Watch whether the Opera Phenix backlog becomes shipments, revenue and cash.
What has Revvity guided for the year ending in January 2027?
On August 4, Revvity guided to revenue of $2.83–$2.86 billion and organic revenue growth of 4.0%–5.0% for the year ending in January 2027. It also guided to adjusted EPS of $5.30–$5.40 and an adjusted operating margin of 28.7%.
| Period guided | Low | High | Date given | |
|---|---|---|---|---|
| Total revenue, pro forma | Year to Jan 2027 | 2.83 | 2.86 | Aug 4, 2026 |
| Pro forma organic revenue growth | Year to Jan 2027 | 4.0% | 5.0% | Aug 4, 2026 |
| Pro forma adjusted earnings per share | Year to Jan 2027 | 5.30 | 5.40 | Aug 4, 2026 |
| Pro forma adjusted operating margins | Year to Jan 2027 | 28.7% | 28.7% | Aug 4, 2026 |
What this means. The company's forecast leaves out China Immunodiagnostics because it is being sold, so these numbers do not cover the whole company as it exists today.
Has Revvity kept its promises?
Adjusted earnings also need inspection. In the second quarter, GAAP EPS was $0.48, while adjusted EPS was $1.41 after selected costs were excluded. Tariff refunds added about $0.11 to adjusted EPS, and favorable tax timing was expected to reverse in the fourth quarter. Revvity’s five-year promises-kept score is 3/5: revenue finished below its assessed range in two years, while adjusted EPS did so in one. The next question is whether analysts see a stronger recovery.
| What management forecast | Checked | Above | Within | Below |
|---|---|---|---|---|
| Revenue | 5 years | 2 | 1 | 2 |
| Adjusted earnings per share | 5 years | 3 | 1 | 1 |
What this means. The three out of five headline is confusing because revenue met or beat the forecast in three years, while adjusted earnings per share met or beat it in four years.
How have Revvity's revenue and profit trended?
In 2025, gross margin fell from 55.8% to 54.8%. Reported operating income rose from $346.7 million to $356.6 million. Adjusted operating income fell from $779.5 million to $773.5 million. Adjusted EPS rose from $4.90 to $5.06 even as adjusted net income fell from $601.2 million to $589.8 million. Fewer shares lifted the per-share result without improving total adjusted earnings.
| Jul 2026 | Apr 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 729,688 | 711,118 | 772,056 | 698,949 | 720,284 | 664,762 | 729,372 | 684,049 |
| Gross margin | 57.1% | 54.5% | 54.6% | 53.6% | 54.5% | 56.5% | 56.5% | 56.3% |
| Operating income | 89,316 | 75,886 | 111,749 | 81,896 | 90,760 | 72,230 | 118,750 | 98,151 |
| Net income | 53,481 | 40,893 | 95,771 | 47,221 | 55,222 | 41,669 | 88,383 | 93,386 |
| EPS, diluted | 0.48 | 0.37 | 0.85 | 0.41 | 0.47 | 0.35 | 0.73 | 0.76 |
What this means. The quarters are not all the same length, because the first quarter of fiscal 2026 had 14 weeks, so its numbers are not perfectly comparable with the others.
What should I watch in Revvity's next results?
At the November 3, 2026 results call, watch whether the Opera Phenix backlog becomes shipments, revenue and cash. Follow-on reagent demand matters because an instrument placement is only the first step. Signals software revenue also needs attention because contract timing can move sales between quarters. Management has included $25 million of full-year Genomics England revenue, so discussion of that relationship will show whether the current outlook is holding.